GlassScriptPhysician profile
Brian Thomas Farrell
NPI 1073766150
$4,868.76
in general payments reported to CMS, 2019-2025
30 companies · $68.59 in 2025
The $68.59 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $1,338 · 2021: $406 · 2022: $397 · 2023: $650 · 2024: $556 · 2025: $68.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090 · Travel and Lodging: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.19 |
| Travel and Lodging | $185.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,277.32 | 2019-2020 | |
| Medtronic, INC. | $897.54 | 2022-2024 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Si-Bone, INC. | $689.88 | 2019-2022 | |
| Cerapedics INC. | $157.20 | 2021-2023 | I-Factor Peptide Enhanced Bone Graft |
| Avanir Pharmaceuticals, INC. | $114.93 | 2019-2022 | |
| Abbvie INC. | $87.23 | 2023 | |
| Zimmer Biomet Holdings, INC. | $61.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $60.75 | 2023 | Austedo, Austedo Xr |
| Jazz Pharmaceuticals INC. | $53.11 | 2019-2023 | |
| Boston Scientific Corporation | $51.05 | 2025 | General - Pain Management |
| Sk Life Science, INC. | $43.34 | 2022-2023 | |
| Ucb, INC. | $41.73 | 2019-2020 | |
| Grifols USA, LLC | $38.34 | 2022 | |
| Livanova USA, INC. | $30.71 | 2019 | |
| Lilly USA, LLC | $24.44 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $22.27 | 2022 | |
| Depuy Synthes Sales INC. | $21.78 | 2019 | |
| Biogen, INC. | $18.81 | 2023 | Skyclarys |
| Banner Life Sciences, LLC | $17.68 | 2022 | |
| Inspire Medical Systems, INC. | $17.54 | 2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $16.78 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.31 | 2022 | |
| Akcea Therapeutics, INC. | $15.94 | 2019 | |
| Neurelis, INC. | $14.10 | 2023 | Valtoco |
| Neurocrine Biosciences, INC. | $14.06 | 2019 | |
| Amgen INC. | $13.37 | 2019 | |
| Abbott Laboratories | $13.13 | 2024 | Eterna |
| Amneal Pharmaceuticals LLC | $12.74 | 2020 | |
| Alexion Pharmaceuticals, INC. | $12.67 | 2021 | |
| Tanabe Pharma America, INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.